A Study to Investigate the Use of Benralizumab in Patients with Bullous Pemphigoid.

Trial Identifier: D325AC00002
Sponsor: AstraZeneca
Start Date: March 2021
Primary Completion Date: October 2023
Study Completion Date: October 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
German Translation
Greek Translation
English Translation
Spanish Translation
French Translation
Hebrew Translation
Italian Translation
Japanese Translation
Russian Translation
Chinese Translation
Bulgarian Translation

Trial Locations

Country Location
AU Kogarah, AU, 2217
AU Parkville, AU, 3050
AU Westmead, AU, 2145
BG Haskovo, BG, 6300
BG Sofia, BG, 1431
CN Beijing, CN, 100730
CN Guangzhou, CN, 510515
CN Hohhot, CN, 10050
CN Shanghai, CN, 200025
DE Bad Bentheim, DE, 48455
DE Bielefeld, DE, 33647
DE Dresden, DE, 01307
DE Leipzig, DE, 04103
ES Alicante, ES, 03010
ES Madrid, ES, 28034
ES Madrid, ES, 28041
FR Lille, FR, 59037
FR MARSEILLE, FR, 13008
FR NICE, FR, 06200
FR Rouen Cedex, FR, 76031
GR Thessaloniki, GR, 56249
IL Ramat Gan, IL, 5262000
IL Tel-Aviv, IL, 64239
IT CATANIA, IT, 95123
IT Florence, IT, 50121
IT Rome, IT, 168
JP Iruma-Gun, JP, 350-0495
JP Kitakyusyu-shi, JP, 806-8501
JP Kurume-shi, JP, 830-0011
JP Okayama, JP, 700-8558
JP Ota-ku, JP, 143-8541
JP Sapporo-shi, JP, 060-8648
JP Urayasu-shi, JP, 279-0021
US, AZ Phoenix, AZ, US, 85006
US, AZ Scottsdale, AZ, US, 85260
US, CO Centennial, CO, US, 80112
US, FL Margate, FL, US, 33063
US, GA Atlanta, GA, US, 30322
US, MA Beverly, MA, US, 01915